GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » FCF Yield %

NDRA (ENDRA Life Sciences) FCF Yield % : -352.01 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ENDRA Life Sciences's Trailing 12-Month Free Cash Flow is $-8.08 Mil, and Market Cap is $2.29 Mil. Therefore, ENDRA Life Sciences's FCF Yield % for today is -352.01%.

The historical rank and industry rank for ENDRA Life Sciences's FCF Yield % or its related term are showing as below:

NDRA' s FCF Yield % Range Over the Past 10 Years
Min: -1591322.31   Med: -217.45   Max: -12.81
Current: -352.01


During the past 10 years, the highest FCF Yield % of ENDRA Life Sciences was -12.81%. The lowest was -1591322.31%. And the median was -217.45%.

NDRA's FCF Yield % is ranked worse than
98.25% of 228 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.85 vs NDRA: -352.01

ENDRA Life Sciences's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


ENDRA Life Sciences FCF Yield % Historical Data

The historical data trend for ENDRA Life Sciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences FCF Yield % Chart

ENDRA Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.17 -42.50 -36.60 -100.62 -43.49

ENDRA Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.26 -39.48 -137.11 -117.84 -176.15

Competitive Comparison of ENDRA Life Sciences's FCF Yield %

For the Diagnostics & Research subindustry, ENDRA Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences's FCF Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's FCF Yield % falls into.



ENDRA Life Sciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ENDRA Life Sciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-9.583 / 22.0374
=-43.49%

ENDRA Life Sciences's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.657 * 4 / 3.7627401
=-176.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ENDRA Life Sciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


ENDRA Life Sciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


ENDRA Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
Michael Milos Thornton officer: Chief Technology Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman director C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon director, officer: Chief Executive Officer 430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova officer: Senior Director, Finance 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells officer: Chief Financial Officer 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc 10 percent owner 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad 10 percent owner 1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105